Capstone Therapeutics Corp. (OTCMKTS:CAPS) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, Bloomberg Earnings reports.

Capstone Therapeutics Corp. (OTCMKTS:CAPS) opened at 0.072 on Tuesday. The stock’s market cap is $2.94 million. The company has a 50 day moving average of $0.06 and a 200-day moving average of $0.07. Capstone Therapeutics Corp. has a 12-month low of $0.04 and a 12-month high of $0.11.

In related news, insider Value Fund L. P. Biotechnology sold 4,341,586 shares of the stock in a transaction that occurred on Friday, July 14th. The shares were sold at an average price of $0.06, for a total value of $260,495.16. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 9.40% of the stock is currently owned by corporate insiders.

WARNING: “Capstone Therapeutics Corp. (CAPS) Posts Earnings Results” was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/capstone-therapeutics-corp-caps-posts-earnings-results/1490136.html.

Capstone Therapeutics Corp. Company Profile

Capstone Therapeutics Corp. is a biotechnology company. The Company is engaged in developing a pipeline of peptides and other molecules aimed at helping patients with under-served medical conditions. The Company entered into a joint venture, LipimetiX Development, Inc, to develop Apo E mimetic peptide molecule AEM-28 and its analogs for the treatment for Homozygous Familial Hypercholesterolemia, Acute Hypertriglyceridemic Pancreatitis, diabetic dyslipidemia and other hyperlipidemic indications.

Receive News & Ratings for Capstone Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capstone Therapeutics Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.